Anavex reports preliminary Q2 FY2026 net loss of $5.3M; cash $127.4M; focuses on FDA for Alzheimer's

ANAVEX LIFE SCIENCES CORP.

Preliminary net loss $5.3M ($0.06/share) vs $11.2M ($0.13/share) in Q2 2025; R&D expenses down to $4.2M from $9.9M.
Cash and equivalents $127.4M as of March 31, 2026, up from $102.6M at Sept 30, 2025; expected to fund operations into mid-to-late FY2028.
Opened IND for early Alzheimer's disease with FDA in March 2026; ADME study expected Q3 2026, DDI study underway.
Aligned with FDA on Phase 3 Rett syndrome protocol for adults; plans to discuss adding pediatric patients.
Submitted plan to regain Nasdaq compliance on July 20, 2026 (Listing Rule 5250(c)(1)).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.